STAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
Why it matters: Drugmakers are innovating market strategies and rare disease treatments, impacting patient access and pharmaceutical development.
- Novo Nordisk appointed Mars CEO Poul Weihrauch as a board observer to strengthen its consumer focus and competitive edge in the U.S. obesity market, as reported by Reuters.
- Novo Nordisk's new management is boosting consumer credentials by launching its Wegovy pill through multiple cash-pay channels, moving beyond solely traditional insurance routes.
- The FDA approved Rocket Pharma’s gene therapy, Kresladi, for severe LAD-1, an ultra-rare disease, after initially rejecting it over manufacturing concerns, STAT notes.
- Rocket Pharma is expected to charge millions for the one-time Kresladi treatment, which, despite not being a major moneymaker due to the rarity of LAD-1, will earn the company a valuable FDA priority review voucher.
Novo Nordisk is strategically bolstering its presence in the competitive U.S. obesity market by appointing Mars CEO Poul Weihrauch as a board observer and expanding its Wegovy pill distribution beyond traditional insurance, a move following a leadership shake-up aimed at enhancing commercial expertise. Concurrently, the FDA approved Rocket Pharma's gene therapy, Kresladi, for the ultra-rare and life-threatening LAD-1, signaling a potential shift in the agency's manufacturing requirements for such innovative treatments.
